Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.44 |
| ▸ | CNR1 | P21554 | 11/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20927117 | 0.98 | CNR2 (0.47) | CNR2CNR1 | |
| SCHEMBL19232176 | 0.94 | CNR2 (0.39) | CNR2CNR1CYP19A1 | |
| SCHEMBL18381788 | 0.85 | CYP19A1 (0.40) | CNR2CNR1CYP19A1 | |
| SCHEMBL22007446 | 0.84 | CYP19A1 (0.37) | CNR2CNR1CYP19A1 | |
| SCHEMBL18909511 | 0.82 | CYP19A1 (0.36) | CNR2CNR1CYP19A1 | |
| SCHEMBL18935500 | 0.82 | CNR2 (0.38) | CNR2CNR1CYP19A1 | |
| SCHEMBL19251056 | 0.82 | CNR2 (0.38) | CNR2CNR1CYP19A1 | |
| SCHEMBL19251185 | 0.82 | CNR2 (0.38) | CNR2CNR1CYP19A1 | |
| SCHEMBL19251174 | 0.82 | CNR2 (0.38) | CNR2CNR1CYP19A1 | |
| SCHEMBL18852713 | 0.81 | CNR2 (0.37) | CNR2CNR1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CNR2 2902/4885CNR1 2040/4885CYP19A1 867/4885 |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | CNR2 347/4885CNR1 695/4885CYP19A1 922/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | CNR2 4387/4885CNR1 4057/4885CYP19A1 231/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CNR2 2902/4885CNR1 2040/4885CYP19A1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.